The Impact of Patient-Centric Formulations on Service Providers...Asma Patel
The article focuses on the role of contract development and manufacturing organizations (CDMOs) in patient-centric drug development, particularly in the context of formulating drugs for rare diseases and cancer treatments. It highlights how patient-centric methodologies have transformed CDMO operati...
| Publicado en: | Pharmaceutical Technology Vol. 50; no. 1; pp. 24 - 26 |
|---|---|
| Autor principal: | |
| Formato: | interview pictorial Journal Article |
| Publicado: |
MJH Life Sciences
Jan/Feb2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191170391&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 191170391 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15432521 4FK jtl: Pharmaceutical Technology issn: 15432521 maglogo: N pubinfo: dt: Jan/Feb2026 vid: 50 iid: 1 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 191170391 191170391 191170391 191170391 ppf: 24 ppct: 2 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: The Impact of Patient-Centric Formulations on Service Providers...Asma Patel aug: au: HAIGNEY, SUSAN sug: subj: Chemistry, Pharmaceutical Patient Centered Care Drug Delivery Systems Contract Services Drugs, Orphan Drug Development Drug Discovery Pharmaceutical Companies Manufacturing Industry Biological Availability Artificial Intelligence Technology, Pharmaceutical Medication Compliance Solubility Drug Approval Collaboration ab: The article focuses on the role of contract development and manufacturing organizations (CDMOs) in patient-centric drug development, particularly in the context of formulating drugs for rare diseases and cancer treatments. It highlights how patient-centric methodologies have transformed CDMO operations, emphasizing the importance of tailored pharmaceutical solutions that enhance patient adherence and convenience. The article discusses the increasing complexity of drug formulations, driven by advanced modalities like peptides and RNA therapies, which has led to greater outsourcing to CDMOs for their specialized expertise. Additionally, it notes that CDMOs are becoming strategic partners in the drug development process, providing integrated solutions that ensure regulatory compliance and optimize manufacturing processes. The anticipated growth in the outsourcing of formulation services is linked to advancements in biotechnology and the adoption of AI and automation technologies. pubtype: Trade Publication doctype: interview pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|